source
- FDA approves Regeneron's siRNA drug Livsayis for myasthenia gravis, expanding its neurology portfolioRegeneron has received FDA clearance for its siRNA‑based therapy cemdisiran, now marketed as Livsayis, to treat myasthenia gravis. This approval is the second new myasthenia gravis drug cleared by…
- Merck partners with Isomorphic Labs to use AI for discovering oncology drug candidatesMerck announced a research collaboration with Isomorphic Labs, an artificial‑intelligence drug design firm, to explore small‑molecule candidates aimed at an undisclosed oncology target. Isomorphic…